Progenity, which sells in vitro molecular tests for prenatal and disease screening, raised $100 million by offering 6.7 million shares at $15, within the range of $14 to $16. Progenity plans to list on the Nasdaq under the symbol PROG. Piper Sandler, Wells Fargo Securities, Baird and Raymond James acted as lead managers on the deal.
